Interviews with the world’s key opinion leaders in cancer

Audio Journal of Oncology

Stefan Paepke MD: An End to “Jumping Breasts” with Mesh Supported Pre-Pectoral Breast Implants

9 months ago

Stefan Paepke MD

Play episode

Sophie Bosma MD PhD:“Young Boost” Trial Finds Low-Dose Radiation Boost Optimal for Young Patients with High-Risk Early Breast Cancer

9 months ago

Sophie Bosma MD PhD

Play episode

Adri Voogd PhD: Ductal Carcinoma in Situ: Good Outcomes from Breast Conserving Therapy, but Benefits, Risks, Costs Still Need to be Optimized

9 months ago

Adri Voogd PhD

Play episode

Annemiek van Hemert MD PhD: “Breast Cancer: MARI Node Marker Helps Most Patients with Extensive Nodal Disease Safely Avoid Axillary Lymph Node Dissection”

9 months ago

Annemiek van Hemert MD PhD

Play episode

Tim Rattay MBChB PhD: Artificial Intelligence Tool Minimizes Arm Lymphedema After Breast Cancer Surgery and Radiotherapy

9 months ago

Tim Rattay MBChB PhD

Play episode

Yasmin Civil MD PhD: Low-Risk ER+ Breast Cancer: ABLATIVE Trial Finds Marked Benefit from MRI-Guided Single-Dose Neoadjuvant Partial Breast Radiotherapy

9 months ago

Partial breast irradiation, given before breast-conserving surgery, achieved durable pathologic complete remissions in low-risk breast...

Play episode

Neo-Adjuvant Pembrolizumab Improved Outcomes with High-Risk ER+ HER2- Early Breast Cancer

9 months ago

Heather McArthur MD MPH

Play episode

Laura J. van ’t Veer PhD: Triple Negative Early Breast Cancer Genetic Sub-Types Predict No Benefit from Neoadjuvant Pembrolizumab

10 months ago

ImPrintTN single-sample classifier identifies no benefit from deoadjuvant pembroliozumab in TNBC

Play episode

Érica A. Oliveira PhD: How to Overcome Drug Resistance: Patient Derived Organoids Study Finds Epigenetic Pathways in Colorectal Cancer

10 months ago

Patient Derived Organoids Shine a Light on Epigenetic Archetypes as Key Drivers of Cancer Drug Resistance LONDON, UK—How to stay ahead with...

Play episode

Christian Singer MD: Neoadjuvant Olaparib Combination Beats Standard of Care in Patients with Homologous Recombination Deficient BRCA 1/2-Positive Triple-Negative Breast Cancer

10 months ago

Homologous Repair Deficient Triple Negative Breast Cancer Positive for BRCA1/2 Mutations Better with Neoadjuvant Olaparib + Carboplatin

Play episode

Rebecca Dent MD: First-Line T-DXd Combination Adds More Than a Year of Progression Free Survival for Patients with Advanced HER2 Positive Breast Cancer

10 months ago

HER2 Positive Advanced Breast Cancer ADC Combination Superior

Play episode

Rebecca Dent MD: First-Line T-DXd Combination Adds More Than a Year of Progression Free Survival for Patients with Advanced HER2 Positive Breast Cancer

11 months ago

Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts)...

Play episode

Audio Journal of Oncology

Audio Journal of Oncology

Menu